Impact of High-Flow Nasal Cannula Use in Subjects With COVID-19 ARDS at High Altitudes: Clinical Presentation and Prognostic Factors.

BACKGROUND: High-flow nasal cannula (HFNC) reduces the need for intubation in adult subject with acute respiratory failure. Changes in hypobaric hypoxemia have not been studied for subject with an HFNC in ICUs at altitudes > 2,600 m above sea level. In this study, we investigated the efficacy of HFN...

Descripción completa

Detalles Bibliográficos
Publicado en:Respiratory Care Vol. 69; no. 1; pp. 99 - 106
Autores principales: Molano-Franco, Daniel, Viruez-Soto, Antonio, Gomez, Mario, Beltran, Edgar, Villabon, Mario, Sosa, Angela, Ortiz, Leidy, Orozco, Estefania, Hurtado, Alejandra, Sanchez, Lida, Arias-Reyes, Christian, Soliz, Jorge, Masclans, Joan R.
Formato: research tables/charts Journal Article
Publicado: Mary Ann Liebert, Inc. Jan2024
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=174595779&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 174595779
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        00201324
        4GG
      jtl: Respiratory Care
      issn: 00201324
      maglogo: N
    pubinfo:
      dt: Jan2024
      vid: 69
      iid: 1
      pid: 1365
      pub: Mary Ann Liebert, Inc.
      place: New Rochelle, New York
    artinfo:
      ui:
        174595779
        174595779
        174595779
        10.4187/respcare.10839
        174595779
      ppf: 99
      ppct: 7
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Impact of High-Flow Nasal Cannula Use in Subjects With COVID-19 ARDS at High Altitudes: Clinical Presentation and Prognostic Factors.
      aug:
        au:
          Molano-Franco, Daniel
          Viruez-Soto, Antonio
          Gomez, Mario
          Beltran, Edgar
          Villabon, Mario
          Sosa, Angela
          Ortiz, Leidy
          Orozco, Estefania
          Hurtado, Alejandra
          Sanchez, Lida
          Arias-Reyes, Christian
          Soliz, Jorge
          Masclans, Joan R.
        affil: Intensive Care Unit Hospital de San José, Foundation University of Health Sciences, CIMCA Research Centre, Bogotá, Colombia
      sug:
        subj:
          Nasal Cannula Utilization
          COVID-19 Risk Factors
          Respiratory Distress Syndrome, Acute Complications
          Human
          Prospective Studies
          Odds Ratio
          Confidence Intervals
          Oxygen Delivery Devices
          Descriptive Research
          Nonexperimental Studies
          Retrospective Design
          Anoxemia
          Data Analysis Software
          Male
          Female
          Respiration, Artificial
          Qualitative Studies
          Quantitative Studies
          Logistic Regression
          Survival Analysis
          Kaplan-Meier Estimator
          Middle Age
          Aged
          Middle Aged: 45-64 years
          Aged: 65+ years
          Male
          Female
      ab: BACKGROUND: High-flow nasal cannula (HFNC) reduces the need for intubation in adult subject with acute respiratory failure. Changes in hypobaric hypoxemia have not been studied for subject with an HFNC in ICUs at altitudes > 2,600 m above sea level. In this study, we investigated the efficacy of HFNC treatment in subjects with COVID-19 at high altitudes. We hypothesized that progressive hypoxemia and the increase in breathing frequency associated with COVID-19 in high altitudes affect the success of HFNC therapy and may also influence the performance of the traditionally used predictors of success and failure. METHODS: This was a prospective cohort study of subjects >18 y with a confirmed diagnosis of COVID-19--induced ARDS requiring HFNC who were admitted to the ICU. Subjects were followed up during the 28 d of HFNC treatment or until failure. RESULTS: One hundred and eight subjects were enrolled. At admission to the ICU, ... delivery between 0.5-0.8 (odds ratio 0.38 [95% CI 0.17-0.84]) was associated with a better response to HFNC therapy than oxygen delivery on admission between 0.8-1.0 (odds ratio 3.58 [95% CI 1.56-8.22]). This relationship continued during follow-ups at 2, 6, 12, and 24 h, with a progressive increase in the risk of failure (odds ratio 24 h 13.99 [95% CI 4.32-45.26]). A new cutoff for the ratio of oxygen saturation (ROX) index (ROX 6 4.88) after 24 h of HFNC administration was demonstrated to be the best predictor of success (odds ratio 11.0 [95% CI 3.3-47.0]). CONCLUSIONS: High-altitude subjects treated with HFNC for COVID-19 showed a high risk of respiratory failure and progressive hypoxemia when ... requirements were > 0.8 after 24 h of treatment. In these subjects, personalized management should include continuous monitoring of individual clinical conditions (such as oxygenation indices, with cutoffs adapted to those corresponding to high-altitude cities).
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N